Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.45 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210718 | 0.89 | CYP11B2 (0.59) | MAPTESR1ESR2AOC3CYP11B2 | |
| SCHEMBL2328330 | 0.88 | ESR2 (0.70) | MAPTESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL1104863 | 0.86 | AOC3 (0.56) | MAPTAOC3CYP11B2CYP11B1G6PD | |
| SCHEMBL2328740 | 0.85 | ESR1 (0.59) | MAPTESR1ESR2AOC3MEN1 | |
| SCHEMBL540960 | 0.84 | AOC3 (0.63) | MAPTESR1ESR2AOC3CYP11B2 | |
| SCHEMBL5580001 | 0.84 | ESR2 (0.68) | MAPTESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL4589408 | 0.82 | ESR1 (0.71) | MAPTESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL2324624 | 0.82 | ESR1 (0.58) | MAPTESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL2213552 | 0.81 | CYP11B2 (0.64) | MAPTAOC3CYP11B2CYP11B1G6PD | |
| SCHEMBL2330121 | 0.80 | ESR1 (0.68) | ESR1ESR2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474415-B1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7683081-B2 | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6962932-B2 | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1474415-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | Schering Aktiengesellschaft (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003068766-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, NFATC1, ICOS | MAPT 98/4885ESR1 4073/4885ESR2 2161/4885 |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, ICOS, NFATC1 | MAPT 229/4885ESR1 4427/4885ESR2 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.